SpringerLink
Log in

Botulinum Toxin in the Management of Painful Conditions

  • Chapter
  • First Online:
Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches

  • 4277 Accesses

Abstract

Botulinum neurotoxin (BoNT) has been used clinically to impair muscle contraction and thereby has become useful in treating conditions characterized by persistent muscle spasticity, muscle spasm, or contraction. It has more recently been found to reduce pain in clinical pain syndromes. This chapter will present the current state of knowledge about the clinical use of BoNT in the treatment of painful conditions. It will also review the mechanism of action of BoNT with regard to inhibition of nociceptive activity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43 suppl 1:s9–15.

    Article  PubMed  Google Scholar 

  2. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci. 1985;12:314–6.

    PubMed  CAS  Google Scholar 

  3. Lew MF, Chinnapongse R, Zhang Y, Corliss M. RimabotulinumB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosurg. 2010;120:2989–3000.

    Google Scholar 

  4. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Lovelace RE, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2:237–54.

    Article  PubMed  CAS  Google Scholar 

  5. Jancovic J, Orman J. Botulinum toxin for cranial cervical dystonia: a double-blind, placebo controlled study. Neurology. 1987;37:616–23.

    Article  Google Scholar 

  6. Freund B, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003;4:159–66.

    Article  PubMed  CAS  Google Scholar 

  7. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement in two distinct mechanisms. Biochem Pharmacol. 2000;59:1403–6.

    Article  PubMed  CAS  Google Scholar 

  8. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion form trigeminal nerve cells by botulinum toxin type A. Implications for migraine therapy. Headache. 2004;44:35–43.

    Article  PubMed  Google Scholar 

  9. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33.

    Article  PubMed  CAS  Google Scholar 

  10. Gazerani P, Staahl C, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006;122:15–25.

    Article  Google Scholar 

  11. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60–9.

    Article  PubMed  CAS  Google Scholar 

  12. Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilation in human skin. Pain. 2007;130:76–83.

    Article  PubMed  CAS  Google Scholar 

  13. Voller B, Sucha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, Auff E, Schider P. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology. 2003;61:940–4.

    Article  PubMed  CAS  Google Scholar 

  14. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. Neurology. 2001;56:1290–3.

    Article  PubMed  CAS  Google Scholar 

  15. Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006;7:260–4.

    Article  PubMed  Google Scholar 

  16. Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicenter study. Pain. 2006;125:82–8.

    Article  PubMed  Google Scholar 

  17. Ferrante FM, Bean L, Rothrock R, King L. Evidence against trigger point injection techniques for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology. 2005;103:377–83.

    Article  PubMed  CAS  Google Scholar 

  18. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivicaine trigger point injections for the treatment of myofascial pain syndrome: A randomized double blind crossover study. Pain. 2005;118:170–5.

    Article  PubMed  CAS  Google Scholar 

  19. Kamanli A, Kaya A, Ardicoglu O, Ozgocmen S, Zengin FO, Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int. 2005;25:604–11.

    Article  PubMed  CAS  Google Scholar 

  20. Ojala T, Arokoski JPA, Partanen J. The effect of small doses of botulinum toxin A on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006;22:90–6.

    Article  PubMed  Google Scholar 

  21. Lucas KR. The impact of latent trigger points on regional muscle function. Curr Pain Headache Rep. 2008;12:344–9.

    Article  PubMed  Google Scholar 

  22. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008;66:1644–51.

    Article  PubMed  Google Scholar 

  23. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23:1662–6.

    Article  PubMed  CAS  Google Scholar 

  24. Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology. 2006;67:241–5.

    Article  PubMed  CAS  Google Scholar 

  25. Gerwin R. Botulinum toxin A in the treatment of headaches. In: Fernádez-de-las-Peñas C, Arendt-Nielsen L, Gerwin RD, editors. Tension-type and cervicogenic headache. Boston: Jones and Bartlett; 2010. p. 431–46.

    Google Scholar 

  26. Silberstein SD, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventative treatment. Headache. 2000;40:445–50.

    Article  PubMed  CAS  Google Scholar 

  27. Evers S, Vollmer-Haase J, Schwaag S, Rahman A, Husstedt I-W, Frese A. Botulinum toxin A in the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled study. Cephalagia. 2004;24:838–43.

    Article  CAS  Google Scholar 

  28. Elkind AH, O’Carroll P, Blumendfeld A, DeGryse R, Dimitrova R, for the BoNTA-024—26—36 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006;7:688–96.

    Article  PubMed  CAS  Google Scholar 

  29. Saper J, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, for the BoNTA-009 study group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med. 2007;8:478–85.

    Article  PubMed  Google Scholar 

  30. Aurora SK, Gawel M, Brandes JL, Pokta S, VanDenburgh AM, for the BOTOX North American Episodic Migraine Study Group. Botulinum toxin type A treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47:486–99.

    Article  PubMed  Google Scholar 

  31. Anand KS, Prasad A, Singh MM, Sharma S, Bala K. Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther. 2006;13:183–7.

    Article  PubMed  CAS  Google Scholar 

  32. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache. 2008;48:201–9.

    PubMed  Google Scholar 

  33. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.

    Article  PubMed  Google Scholar 

  34. Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49(10):1466–78.

    Article  PubMed  Google Scholar 

  35. Tfelt-Hansen P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine attacks. Headache. 1981;21(2):49–54.

    Article  PubMed  CAS  Google Scholar 

  36. Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, Di Ianni L, Lapenna D, Mezzetti A. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007;8(11):869–78. Epub 2007 Aug 9.

    Article  PubMed  Google Scholar 

  37. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgender JM. Effect of botulinum toxin A injections in the treatment of chronic tension type headache: a double-blind, placebo-controlled trial. Headache. 2001;41:658–64.

    Article  PubMed  CAS  Google Scholar 

  38. Schulte-Mattler WJ, Krack P, BoNTTH Study Group. Treatment of chronic tension type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109:110–4.

    Article  PubMed  CAS  Google Scholar 

  39. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C. Botulinum toxin type A in the prophylactic treatment of chronic tension type headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Cephalagia. 2006;26:790–800.

    Article  CAS  Google Scholar 

  40. Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, Joseph P, Lee TS, Houle TT. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache. 2009;49:732–43.

    Article  PubMed  Google Scholar 

  41. Fernandez-de-las-Peñas C, Arendt-Nielsen L, Gerwin RD. Tension-type and cervicogenic headache. Boston: Jones and Bartlett; 2010. p. 61–89.

    Google Scholar 

  42. Hamdy SM, Samir H, El-Sayed M, Adel N, Hasan R. Botulinum toxin: could it be an effective treatment for chronic tension-type headache? J Headache Pain. 2009;10:27–34.

    Article  PubMed  CAS  Google Scholar 

  43. Venancio RA, Alencar Jr FG, Zamperini C. Botulinum toxin, lidocaine, and dry needling injections in patients with myofascial pain and headaches. Cranio. 2009;27:46–53.

    Google Scholar 

  44. Jarvis SK, Abbott JA, Lenart MB, Steensma A, Vancaillie TG. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44:46–50.

    Article  PubMed  Google Scholar 

  45. Romito S, Bottarnelli M, Pellegrini M, Vicentini S, Rizzulo N, Bertolasi L. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest. 2004;58:164–7.

    Article  PubMed  CAS  Google Scholar 

  46. Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr Drug Deliv. 2010;7:1–4.

    Article  PubMed  CAS  Google Scholar 

  47. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64:871–5.

    Article  PubMed  Google Scholar 

  48. Kuo HC. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int. 2005;75:170–4.

    Article  PubMed  CAS  Google Scholar 

  49. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70:463–8.

    Article  PubMed  Google Scholar 

  50. Dykstra DO, Presthus J. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. J Reprod Med. 2006;51:467–70.

    PubMed  CAS  Google Scholar 

  51. Brown CS, Glazer Hl, Vogt V, Menkes D, Bachman G. Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot study. J Reprod Med. 2006;51:635–41.

    PubMed  CAS  Google Scholar 

  52. Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, Landman J. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183:598–602.

    Article  PubMed  CAS  Google Scholar 

  53. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009;25(7):1573–84. Review.

    Article  PubMed  CAS  Google Scholar 

  54. Boon AJ, Smith J, Dahm DL, Sorenson EJ, Larson DR, Fitz-Gibbon PD, Dykstra DD, Singh JA. Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R. 2010;2:268–76.

    Article  PubMed  Google Scholar 

  55. Singer BJ, Silbert PL, Song S, Dunne JW, Singer KP. Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: a randomized placebo controlled crossover trial. Br J Sports Med. 2011;45(8):640–5. Epub 2010 Apr 23.

    Article  PubMed  Google Scholar 

  56. Lee JH, Lee SH, Song SH. Clinical effectiveness of botulinum toxin A compared to a mixture of steroid and local anesthetics as a treatment for sacroiliac joint pain. Pain Med. 2010;11(5):692–700.

    Article  PubMed  Google Scholar 

  57. Yelnik PP, Colle FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomized, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry. 2007;78:845–6.

    Article  PubMed  Google Scholar 

  58. de Boer KS, Arwert HJ, de Groot JH, Meskers CG, Mishre AD, Arendzen JH. Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle. J Neurol Neurosurg Psychiatry. 2008;79:581–3.

    Article  PubMed  Google Scholar 

  59. Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain. Stroke. 2008;39:126–31.

    Article  PubMed  CAS  Google Scholar 

  60. von Lindern JJ, Niederhagan B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61:774–8.

    Article  Google Scholar 

  61. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin A: a short-term, randomized, placebo-controlled, double-blind study. Am J Phys Med Rehabil. 2005;84:649–54.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, School of Medicine, Johns Hopkins University School of Medicine, 7830 Old Georgetown Road, Suite C15, Bethesda, MD, 20814, USA

    Robert Gerwin M.D.

Authors
  1. Robert Gerwin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Gerwin M.D. .

Editor information

Editors and Affiliations

  1. The Center for Pain Relief, Inc., West Virginia University, 400 Court Street, Suite 100, Charleston, 25301, West Virginia, USA

    Timothy R. Deer

  2. Stanford Pain Management Center, Redwood City, CA, Clinic Chief, Stanford University School of Medicine, Stanford, 94065, California, USA

    Michael S. Leong

  3. Department of Anesthesiology, Rush Medical College, Professor, Rush University Medical Center, Chicago, 60612, Illinois, USA

    Asokumar Buvanendran

  4. Pennsylvania State University, College of Medicine, Department of Anesthesiology, Milton S. Hershey Medical Center, Hershey, 17033-0850, Pennsylvania, USA

    Vitaly Gordin

  5. Center for Interventional Pain and Spine, Newark, DE USA, Medical Director, Bryn Mawr Hospital, Bryn Mawr, 19010, Pennsylvania, USA

    Philip S. Kim

  6. President, National Institute of Pain, Tampa, 33558, Florida, USA

    Sunil J. Panchal

  7. The LITE Center, Clinical Associate Professor, Medical Director, School of Medicine, Miami, 33143, Florida, USA

    Albert L. Ray

Rights and permissions

Reprints and permissions

Copyright information

© 2013 American Academy of Pain Medicine

About this chapter

Cite this chapter

Gerwin, R. (2013). Botulinum Toxin in the Management of Painful Conditions. In: Deer, T., et al. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1560-2_54

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1560-2_54

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-1559-6

  • Online ISBN: 978-1-4614-1560-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation